カルナバイオサイエンス(株)
株価チャート
2026/08/03 更新株価トレンド
2026/08/03 更新株価・取引詳細
2026/08/03 更新株価
取引
株主構成
2026/08/01 更新大株主
2026/08/01 更新| 機関名 | 保有比率 | 保有株数 | 変化 |
|---|---|---|---|
|
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF
|
4.4K | 0.00% |
財務パフォーマンス
2026/08/02 更新売上・利益
利益率
キャッシュフロー
財務健全性
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| 損益計算書 | ||||
| 売上高 | ¥14億 | ¥16億 | ¥6億 | ¥6億 |
| 売上総利益 | ¥12億 | ¥15億 | ¥5億 | ¥4億 |
| 営業利益 | -¥13億 | -¥11億 | -¥21億 | -¥21億 |
| 経常利益 | -¥13億 | -¥11億 | -¥22億 | -¥22億 |
| 当期純利益 | -¥13億 | -¥12億 | -¥22億 | -¥22億 |
| EPS | -¥99.10 | -¥68.62 | -¥121.64 | -¥113.62 |
| 営業利益率 | -91.57% | -68.70% | -326.31% | -358.34% |
| 貸借対照表 | ||||
| 総資産 | ¥43億 | ¥43億 | ¥28億 | ¥12億 |
| 純資産 | ¥36億 | ¥39億 | ¥25億 | ¥3億 |
| 総負債 | ¥6億 | ¥5億 | ¥3億 | ¥9億 |
| 現金 | ¥34億 | ¥29億 | ¥21億 | ¥5億 |
| 有利子負債 | ¥3億 | ¥2億 | ¥1億 | ¥7億 |
| 自己資本比率 | 85.36% | 89.14% | 89.29% | 25.15% |
| D/Eレシオ | 0.08 | 0.05 | 0.02 | 2.31 |
| キャッシュフロー | ||||
| 営業CF | -¥7億 | -¥17億 | -¥14億 | -¥22億 |
| 投資CF | -¥1億 | -¥0億 | -¥0億 | -¥0億 |
| 財務CF | ¥4億 | ¥12億 | ¥6億 | ¥6億 |
| フリーCF | -¥8億 | -¥17億 | -¥14億 | -¥22億 |
| 効率性 | ||||
| ROE | -37.06% | -29.73% | -88.01% | -702.25% |
| ROA | -31.63% | -26.50% | -78.59% | -176.59% |
最新IR情報
最新ニュース (5件)
企業情報
会社概要
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP and AFP-Glo assay; and cell-based assay services which include NanoBRET TE intracellular kinase assay and split luciferase protein-protein interaction detection assay. In addition, it engages in developing monzosertib, an orally bioavailable small molecule inhibitor of cell division cycle 7 (CDC7) kinase that is in Phase 1 to treat various cancer cell lines, including solid and blood cancers; docirbrutinib, an orally bioavailable, non-covalent pan-inhibitor of wild type and mutant Bruton's tyrosine kinases for the treatment of chronic lymphocytic leukemia and other B-cell malignancies; and sofnobrutinib, a non-covalent Bruton's tyrosine kinases which is in clinical development to treat inflammatory and immune disorders. Carna Biosciences, Inc. was incorporated in 2003 and is headquartered in Kobe, Japan.
